Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4743015 | 1.00 | KDM4E (0.33) | KDM4ERAB9A | |
| SCHEMBL860525 | 0.65 | — | — | |
| SCHEMBL860526 | 0.65 | — | — | |
| SCHEMBL25428148 | 0.64 | TSHR (0.37) | KDM4E | |
| SCHEMBL5429756 | 0.62 | ALDH1A1 (0.35) | — | |
| SCHEMBL15751859 | 0.62 | — | — | |
| SCHEMBL4591310 | 0.61 | — | — | |
| SCHEMBL11037082 | 0.60 | FBP1 (0.30) | — | |
| SCHEMBL6442639 | 0.59 | LMNA (0.37) | RAB9A | |
| SCHEMBL6442643 | 0.59 | LMNA (0.37) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0115811-B1 | 2,4-DICHLOR-5-THIAZOLECARBOXALDEHYD AND A PROCESS FOR ITS PREPARATION | BAYER AG (DE) | 1990-04-18 | — | — | EP | claimed |
| US-4555577-A | 2,4-Dichloro-5-thiazolecarboxaldehyde and a process for its preparation | BAYER AKTIENGESELLSCHAFT (DE) | 1985-11-26 | — | — | US | claimed |
| EP-0115811-A2 | 2,4-Dichlor-5-thiazolecarboxaldehyd and a process for its preparation | BAYER AG (DE) | 1984-08-15 | — | — | EP | claimed |
| US-8748627-B2 | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| EP-1999119-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | Abbott Laboratories (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20070225332-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC. | 2007-09-27 | — | — | US | disclosed |
| WO-2007095602-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225332-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | KDM4E 2564/4885RAB9A 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.